Page 6 - கிலியட் சாலை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கிலியட் சாலை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கிலியட் சாலை Today - Breaking & Trending Today

"עובדי פסגות לא למכירה": מפגינים מול ביתו של גלעד אלטשולר

"עובדי פסגות לא למכירה": מפגינים מול ביתו של גלעד אלטשולר
ynet.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ynet.co.il Daily Mail and Mail on Sunday newspapers.

Altschuler Shaham , R Committee Shlomi Logsdon , Gilead Altschuler , Goldilocks Cohen , Altschuler Shaham More ,

Kidney problems unrelated to remdesivir: EU regulator

Europe’s drugs regulator said on Friday its safety panel found no evidence that Gilead’s remdesivir caused kidney problems in some COVID-19 patients. ....

European Medicines Agency , Medicines Agency , Covid 19 ,

Galapagos and Gilead to end late-stage studies of lung disease drug

Galapagos and Gilead to end late-stage studies of lung disease drug
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Gilead Sciences Inc , Experimental Drug , Pulmonary Fibrosis , Galapagos Nv , கிலியட் அறிவியல் இன்க் , சோதனை மருந்து , நுரையீரல் ஃபைப்ரோஸிஸ் , க்யாலபாகொஸ் ந்வ் ,

Galapagos, Gilead Discontinue Late-stage Trials In Idiopathic Pulmonary Fibrosis

FOSTER CITY (dpa-AFX) - Galapagos NV (GLPG) and Gilead Sciences (GILD) said that they have decided to discontinue the ISABELA Phase 3 studies with the investigational autotaxin inhibitor ziritaxestat ....

Gilead Sciences , Data Monitoring Committee , Independent Data Monitoring Committee , கிலியட் அறிவியல் , தகவல்கள் கண்காணிப்பு குழு , சுயாதீனமான தகவல்கள் கண்காணிப்பு குழு ,

Gilead forecasts 2021 growth, strong remdesivir COVID-19 sales

3 Min Read
(Reuters) - Gilead Sciences Inc on Thursday forecast its 2021 results above Wall Street estimates after posting a 26% rise in fourth-quarter 2020 revenue, driven by sales of its antiviral drug, remdesivir, which is used to treat COVID-19 patients.
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake
Shares of Gilead were up 2.5% in extended trading.
Gilead said the COVID-19 pandemic continues to affect its sales, including its treatments for hepatitis C and HIV, due to fewer people going to their doctors. It expects a gradual recovery in underlying market dynamics starting the second quarter of this year. ....

United States , Karishma Singh , Michael Yee , Vishwadha Chander , Merdad Parsey , Thomson Reuters Trust Principles , Gilead Sciences Inc On , Sciences Inc , Wall Street , Chief Medical Officer Merdad Parsey , Anild Silva , Thomson Reuters Trust , Bio Therapeutic Drugs Trbc Level 5 , Content Produced In Bangalore , Company News , Healthcare Trbc Level 1 , Biotechnology Amp Medical Research Trbc Level 4 , Major News , Pharmaceuticals Trbc Level 4 , Pharmaceuticals Amp Medical Research Trbc Level 2 , Performance Results Earnings , Results Forecasts Warnings , Reuters Top News , ஒன்றுபட்டது மாநிலங்களில் , கரிஷ்மா சிங் , மைக்கேல் யீ ,